Older adults should not be omitted from inclusion in clinical trials of SARS-CoV-2 vaccines.

Guillaume Sacco Thomas Célarier Gaetan Gavazzi Cédric Annweiler

Maturitas

Department of Geriatric Medicine and Memory Clinic, Research Center on Autonomy and Longevity, University Hospital, Angers, France; UPRES EA 4638, Université d'Angers, Angers, France; Robarts Research Institute, Department of Medical Biophysics, Schulich School of Medicine and Dentistry, the University of Western Ontario, London, ON, Canada.

Published: April 2021

Download full-text PDF	Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7537629	PMC
http://dx.doi.org/10.1016/j.maturitas.2020.10.002	DOI Listing

Publication Analysis

Top Keywords

older adults

adults inclusion

inclusion clinical

clinical trials

trials sars-cov-2

sars-cov-2 vaccines

older

inclusion

clinical

trials

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!